Glenmark Pharmaceuticals Recalls 1.5 Million Bottles of Generic ADHD Drug
Glenmark Pharmaceuticals, Inc., a subsidiary of Glenmark Pharmaceuticals Ltd. of Mumbai, India, is recalling 1.476 million bottles of a generic Attention Deficit Hyperactivity Disorder (ADHD) medication called atomoxetine from the U.S market, according to the U.S. Food and Drug Administration (FDA).1 Eli Lilly had once marketed the branded version of the drug, Strattera, but stopped […]